Caren Logo
Pre-Therapy Antineoplastic Screening
Pre-Therapy Antineoplastic Screening

Reference for building the Care Pathway:

STAR (Systemic Therapy Assessment Routine)

This protocol was initially developed and implemented in oncology centers in the United Kingdom and Canada, aiming to standardize the assessment prior to the administration of antineoplastic therapy.

It is based on guidelines from major oncology societies, such as:
National Comprehensive Cancer Network (NCCN – USA), American Society of Clinical Oncology (ASCO – USA), European Society for Medical Oncology (ESMO – Europe), British Oncology Pharmacy Association (BOPA – United Kingdom)
Cancer Care Ontario (CCO – Canada)

Caren has adopted the guidelines of this protocol as a reference to structure its care pathway, aiming to assess whether patients are fit to receive treatment, minimizing the risk of severe toxicity and optimizing clinical outcomes.

Tags Plans and prices >

Care Pathway for Pre-Therapy Antineoplastic Screening

Caren's care pathway continuously evaluates patient data during oncology treatment. The system enables early detection of signs of complications, toxicities, or the need for adjustments in antineoplastic therapy. The platform integrates information from clinical questionnaires, adherence to the therapeutic protocol, laboratory tests, reported symptoms, and indicators of physical and emotional well-being. This data is analyzed in real time to generate personalized alerts for healthcare teams, ensuring safe, accurate, and proactive monitoring.
📋 Steps:
1
Pre-Therapy Antineoplastic Screening
✅ Main objectives:
  • ✔ Identify early risks of severe toxicity, preventing serious adverse events.
  • ✔ Adjust doses and protocols based on the patient's clinical and laboratory status.
  • ✔ Minimize side effects and ensure that the treatment is well tolerated.
  • ✔ Standardize criteria for indicating, postponing, or adjusting systemic therapy.
📌 Expected benefits:
  • ✔ Prevention of severe toxicities such as liver, kidney, and hematologic failure.
  • ✔ Early identification of factors that may lead to therapy discontinuation.
  • ✔ Better toxicity management enables the continuation of oncology treatment.
  • ✔ Safer therapeutic decisions based on objective data.
⚡Test now:
Dialog Chatbot